Navigation Links
Halozyme Therapeutics Added to Nasdaq Biotech Index
Date:11/12/2007

SAN DIEGO, Nov. 12 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products based on the extracellular matrix, today announced that it has been selected for addition to the NASDAQ Biotechnology Index(R) (Nasdaq: NBI), effective Monday, November 19.

Launched in 1993, the NASDAQ Biotechnology Index is ranked on a semi-annual basis in May and November and serves as the basis for the iShares NASDAQ Biotechnology Fund (Amex: IBB). Securities included in the NASDAQ Biotechnology Index must be listed on the NASDAQ National Market and be classified according to the FTSE(TM) Global Classification System as either biotechnology or pharmaceutical. Additionally, securities in the index must meet minimum requirements for market value, average daily share volume and seasoning as a public company, among other criteria. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit http://www.nasdaq.com.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products based on the extracellular matrix for the drug delivery, oncology and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.

Halozyme Contact Investor Relations Contact

David A. Ramsay Don Markley

Chief Financial Officer Lippert/Heilshorn & Associates

(858) 704-8260 (310) 691-7100

dramsay@halozyme.com dmarkley@lhai.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Prime Therapeutics Receives TIPPS Certification
2. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
3. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
4. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
7. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
8. Prime Therapeutics Announces URAC Accreditation
9. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
10. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... , ... July 28, 2017 , ... James M. Maisel, ... to have chaired the Epidemiology and Prevention of Diabetes section at the 5th World ... also chairman of Retina Group of New York and recipient of the Juvenile Diabetes ...
(Date:7/28/2017)... ... 2017 , ... The United States Department of Agriculture (USDA) ... , Right now the most public debate is over the Supplemental Nutrition Assistance ... under consideration, including WIC (Women, Infants, and Children), which is the country’s third-largest ...
(Date:7/28/2017)... ... July 28, 2017 , ... The DuPage County law firm of Mirabella ... M. Cusack. Ms. Cusack joins the team ready to provide clients with vigorous ... Bradley University in Peoria, Illinois, with a BA in Social Work. She earned her ...
(Date:7/28/2017)... ... July 28, 2017 , ... For over 20 years Sealy Baby has been ... babies. We take tremendous pride in using some of nature’s best materials while integrating ... and innovative crib mattresses and crib bedding for infants and ...
(Date:7/28/2017)... ... July 28, 2017 , ... Leyden Insurance Agency, a Chicago based firm ... and around Cook County, is working in conjunction with the Conner T. Lowry Memorial ... Established in honor of a brave soldier who is still dearly missed by his ...
Breaking Medicine News(10 mins):
(Date:7/25/2017)... and CAMBRIDGE, Massachusetts , July 25, 2017 ... repurposing drugs to treat rare nervous system diseases, has concluded ... develop and market the drug SOM0226 against transthyretin amyloidosis (ATTR). ... very promising results in a Phase 2 study conducted in ... office in the United States ...
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July ... UTHR ) announced today that it will report ... opens on Thursday, July 27, 2017. ... on Thursday, July 27, 2017, at 9:00 a.m. Eastern ... international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference ...
(Date:7/17/2017)... ORLANDO, Fla. , July 17, 2017  MedX ... - branded medical testing, strengthening and rehabilitation equipment, today ... Back Machine Program. MedX is considered the gold standard ... world leader in specialized medical strengthening equipment. ... into a lease with the physician or practice who ...
Breaking Medicine Technology: